Masimo (MASI) Jefferies 2024 Global Healthcare Conference summary

Business evolution and strategic direction

• Core healthcare business remains focused on pulse oximetry, with strong market share gains and a $2.5–$3 billion addressable market.

• Healthcare revenues guided at $1.365 billion, with 70–75% from SET pulse oximetry and high growth in Rainbow, capnography, and brain monitoring.

• Expansion into consumer health with new products and a recent acquisition, now considering an accelerated separation due to investor feedback.

• Evaluating a spin-off or sale of the consumer business, aiming to return to a 30% operating margin profile for the core business.

• Proceeds from a sale would be prioritized for debt reduction, with a sale expected to close in 3–6 months versus 12 months for a spin.

Separation structure and intellectual property

• Separation would involve licensing core technology to the consumer entity, with healthcare retaining all core IP except for consumer audio and hearables.

• Sensor module IP may be licensed back to healthcare for specific products, ensuring a clean structure and minimizing internal competition.

• Structure mirrors existing OEM licensing arrangements, aiming for clarity and minimal disruption.

Financial outlook and margin expansion

• Pro forma core healthcare margins estimated at 23–25% post-separation, with a target of 30% operating margin over six years.

• Margin expansion driven by manufacturing efficiencies, especially from transitioning to Malaysia, and ongoing cost reductions.

• Gross margin improvements expected, with a long-term goal of 66% and potential to reach 70% gross and 35% operating margins beyond six years.